LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)
Publication/Presentation Date
11-2020
Volume
22
Issue
2
First Page
237
Last Page
237
Published In/Presented At
Zadeh, G., Daras, M., Cloughesy, T. F., Colman, H., Kumthekar, P. U., Chen, C. C., Aiken, R., Groves, M. D., Ong, S., Ramakrishna, R., Vogelbaum, M. A., Khagi, S., Kaley, T., Melear, J. M., Peereboom, D. M., Rodriguez, A., Yankelevich, M., Nair, S. G., Puduvalli, V. K., Nassiri, F., … Lang, F. F. (2020). LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). Neuro-Oncology, 22(Suppl 2), ii237. https://doi.org/10.1093/neuonc/noaa215.989
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute
Document Type
Article
COinS